AR103219A1 - Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento - Google Patents
Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamentoInfo
- Publication number
- AR103219A1 AR103219A1 ARP150104227A ARP150104227A AR103219A1 AR 103219 A1 AR103219 A1 AR 103219A1 AR P150104227 A ARP150104227 A AR P150104227A AR P150104227 A ARP150104227 A AR P150104227A AR 103219 A1 AR103219 A1 AR 103219A1
- Authority
- AR
- Argentina
- Prior art keywords
- propan
- indole
- manufacture
- pharmaceutical composition
- compound
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- KMVYYLYKRGELJE-UHFFFAOYSA-N 1-(1h-indol-3-yl)propan-1-one Chemical compound C1=CC=C2C(C(=O)CC)=CNC2=C1 KMVYYLYKRGELJE-UHFFFAOYSA-N 0.000 abstract 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- JYZATACFRNCXLC-DMPGVRBJSA-N (2R)-2-[[3-(3,5-dichloropyridin-4-yl)-1,2-dihydro-1,2,4-triazol-3-yl]sulfanyl]-1-(1H-indol-3-yl)propan-1-one Chemical compound ClC=1C=NC=C(C=1C1(NNC=N1)S[C@@H](C(=O)C1=CNC2=CC=CC=C12)C)Cl JYZATACFRNCXLC-DMPGVRBJSA-N 0.000 abstract 1
- BAABPIIOLPSIKR-SECBINFHSA-N (2R)-2-[[5-(3,5-dichloropyridin-4-yl)-1H-1,2,4-triazol-3-yl]sulfanyl]-1-(1H-indol-3-yl)propan-1-one Chemical compound ClC=1C=NC=C(C=1C1=NNC(=N1)S[C@@H](C(=O)C1=CNC2=CC=CC=C12)C)Cl BAABPIIOLPSIKR-SECBINFHSA-N 0.000 abstract 1
- -1 (3- (3,5-dichloropyridin-4-yl)) -1H-1,2,4-triazol-5-yl Chemical group 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de (1H-indol-3-il)propan-1-ona que tiene la fórmula (1) (R)-2-((3-(3,5-dicloropiridin-4-il)-1H-1,2,4-triazol-5-il)tio)-1-(1H-indol-3-il)propan-1-ona o una de sus formas tautómeras, en donde la forma tautómera es de la fórmula (2) (R)-2-((3-(3,5-dicloropiridin-4-il)-1H-1,2,4-triazol-3-il)tio)-1-(1H-indol-3-il)propan-1-ona, o una sal farmacéuticamente aceptable de los mismos. Composición farmacéutica que comprende dicho compuesto, una de sus formas tautómeras, o una de sus sales farmacéuticamente aceptables; y uno o más excipientes farmacéuticamente aceptables. Combinaciones y mezclas que lo comprenden. Uso del compuesto para la fabricación de un medicamento para el tratamiento de una infección parasitaria protozoaria, siendo dicha infección la malaria, preferentemente causada por Plasmodium falciparum. Reivindicación 1: Un compuesto de (1H-indol-3-il)propan-1-ona caracterizado porque que tiene la fórmula (1) (R)-2-((3-(3,5-dicloropiridin-4-il)-1H-1,2,4-triazol-5-il)tio)-1-(1H-indol-3-il)propan-1-ona o una de sus formas tautómeras.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382555 | 2014-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103219A1 true AR103219A1 (es) | 2017-04-26 |
Family
ID=52146396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104227A AR103219A1 (es) | 2014-12-22 | 2015-12-21 | Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170368034A1 (es) |
| EP (1) | EP3237400A1 (es) |
| JP (1) | JP2017538776A (es) |
| KR (1) | KR20170097051A (es) |
| CN (1) | CN107108572A (es) |
| AR (1) | AR103219A1 (es) |
| AU (1) | AU2015371169A1 (es) |
| BR (1) | BR112017013545A2 (es) |
| CA (1) | CA2971668A1 (es) |
| PE (1) | PE20171081A1 (es) |
| PH (1) | PH12017501072A1 (es) |
| RU (1) | RU2017126044A (es) |
| SG (1) | SG11201704584RA (es) |
| TW (1) | TW201636340A (es) |
| UY (1) | UY36469A (es) |
| WO (1) | WO2016102431A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20200102A7 (es) * | 2018-06-19 | 2021-08-06 | Novartis Ag | Compuestos derivados de isoindolin-1,2,4-triazol-3-carbonitrilo útiles para el tratamiento de enfermedades cinetoplastídicas |
| CA3162386A1 (en) * | 2019-12-18 | 2021-06-24 | Glen N. Barber | Substituted 1,2, 4-triazoles and methods of use |
-
2015
- 2015-12-21 RU RU2017126044A patent/RU2017126044A/ru unknown
- 2015-12-21 US US15/537,637 patent/US20170368034A1/en not_active Abandoned
- 2015-12-21 AU AU2015371169A patent/AU2015371169A1/en not_active Abandoned
- 2015-12-21 BR BR112017013545A patent/BR112017013545A2/pt not_active Application Discontinuation
- 2015-12-21 WO PCT/EP2015/080730 patent/WO2016102431A1/en active Application Filing
- 2015-12-21 TW TW104142896A patent/TW201636340A/zh unknown
- 2015-12-21 AR ARP150104227A patent/AR103219A1/es unknown
- 2015-12-21 SG SG11201704584RA patent/SG11201704584RA/en unknown
- 2015-12-21 PE PE2017000989A patent/PE20171081A1/es not_active Application Discontinuation
- 2015-12-21 KR KR1020177017016A patent/KR20170097051A/ko unknown
- 2015-12-21 JP JP2017533570A patent/JP2017538776A/ja active Pending
- 2015-12-21 CN CN201580070247.3A patent/CN107108572A/zh active Pending
- 2015-12-21 CA CA2971668A patent/CA2971668A1/en not_active Abandoned
- 2015-12-21 EP EP15817827.7A patent/EP3237400A1/en not_active Withdrawn
- 2015-12-21 UY UY0001036469A patent/UY36469A/es unknown
-
2017
- 2017-06-08 PH PH12017501072A patent/PH12017501072A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3237400A1 (en) | 2017-11-01 |
| TW201636340A (zh) | 2016-10-16 |
| KR20170097051A (ko) | 2017-08-25 |
| CA2971668A1 (en) | 2016-06-30 |
| PE20171081A1 (es) | 2017-08-03 |
| UY36469A (es) | 2016-06-30 |
| AU2015371169A1 (en) | 2017-06-29 |
| WO2016102431A1 (en) | 2016-06-30 |
| PH12017501072A1 (en) | 2017-11-27 |
| BR112017013545A2 (pt) | 2018-03-06 |
| JP2017538776A (ja) | 2017-12-28 |
| US20170368034A1 (en) | 2017-12-28 |
| CN107108572A (zh) | 2017-08-29 |
| RU2017126044A (ru) | 2019-01-24 |
| SG11201704584RA (en) | 2017-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2018001510A1 (es) | Composición farmacéutica que comprende un potente inhibidor de urat1 | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| CL2018001830A1 (es) | Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| NI201800071A (es) | Compuestos de isoindol | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| ECSP19019613A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| DOP2023000251A (es) | Compuestos oligoméricos que inhiben la expresión de hsd17b13 | |
| SV2016005313A (es) | Derivados de carboxamida | |
| DOP2019000071A (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos | |
| AR103219A1 (es) | Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento | |
| SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| UY36084A (es) | Activadores de herg policíclicos | |
| NI202000017A (es) | Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos | |
| UY33806A (es) | ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |